Clinical Trials

Trametinib has been evaluated in numerous clinical trials spanning Early Phase 1 through Phase 4 for various oncological and vascular disorders, including BRAF V600-mutated melanoma, solid tumors, non-small cell lung cancer, anaplastic thyroid cancer, acute myeloid leukemia, neurofibromatosis 1, and arteriovenous malformations. Sponsored by pharmaceutical companies and academic institutions such as Novartis and M.D. Anderson Cancer Center, these investigations display varied recruitment statuses, including actively recruiting, completed, not yet recruiting, and withdrawn.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06582745 RECRUITING
Langerhans Cell Histiocytosis
Cook Children's Health Care System
 2024-06-24 PHASE2
NCT06119789 RECRUITING
Rare Malignant Neoplasm
Oslo University Hospital
 2025-03-20 PHASE2
NCT03340506 RECRUITING
Melanoma; Non Small Cell Lung Cancer; Solid Tumor; Rare Cancers; High Grade Glioma
Novartis Pharmaceuticals
 2018-01-26 PHASE4
NCT07110246 RECRUITING
BRAF V600 Mutation; Low-grade Glioma; Low Grade Glioma of Brain; Recurrent Low Grade Glioma
University of California, San Francisco
 2025-11-07 PHASE2
NCT05180825 RECRUITING
Grade 1 Glioma; Mixed Glio-neuronal Tumors; Pleomorphic Xanthoastrocytoma
University Hospital, Strasbourg, France
 2022-05-05 PHASE2
NCT06475989 RECRUITING
Refractory Differentiated Thyroid Gland Carcinoma
ECOG-ACRIN Cancer Research Group
 2024-08-22 PHASE3
NCT05722886 RECRUITING
Haematological Malignancy; Solid Tumour
Cancer Research UK
 2023-03-01 PHASE2; PHASE3
NCT07440290 RECRUITING
Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Gastrointestinal Cancer; Non-Melanoma Skin Cancer (NMSC); Langerhans Cell Histiocytosis (LCH); Cancer; Erdheim-Chester Disease; Thyroid Carcinoma, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small Cell-Lung; Glioma; Multiple Myeloma; Thyroid Carcinoma, Anaplastic; Solid Tumour; Pancreatic Diseases
Cancer Research UK
 2026-04-01 PHASE2; PHASE3
NCT07549646 ACTIVE_NOT_RECRUITING
Ras/MAPK Pathway Vascular Anomalies; Vascular Anomalies; Vascular Anomaly
Children's Hospital of Philadelphia
 2025-08-27 PHASE2
NCT03899155 RECRUITING
Cancer
Bristol-Myers Squibb
 2019-08-09 PHASE2
NCT07468071 RECRUITING
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer; Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
 2026-06-08 PHASE1; PHASE2
NCT05658640 RECRUITING
Acute Lymphoblastic Leukemia, in Relapse; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
Princess Maxima Center for Pediatric Oncology
 2023-11-14 PHASE1; PHASE2
NCT04803318 RECRUITING
Solid Tumor, Adult; Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University
 2021-01-01 PHASE2
NCT06712875 RECRUITING
Low Grade Glioma; High Grade Glioma
Ann & Robert H Lurie Children's Hospital of Chicago
 2025-04-01 PHASE1; PHASE2
NCT05849662 RECRUITING
Leukemia, Juvenile Myelomonocytic; JMML; JCML; Neurofibromatosis 1; CBL Syndrome
Therapeutic Advances in Childhood Leukemia Consortium
 2024-10-11 PHASE1; PHASE2
NCT06819605 NOT_YET_RECRUITING
Ameloblastoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
 2025-03-01 PHASE2; PHASE3
NCT04903119 RECRUITING
Metastatic Melanoma; BRAF Gene Mutation
Rina Plattner
 2022-06-01 PHASE1
NCT07022834 RECRUITING
Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital
 2025-06-01 PHASE2
NCT07131059 RECRUITING
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China
 2024-05-11
NCT06346067 ACTIVE_NOT_RECRUITING
Advanced or Metastatic NRAS-mutant Melanoma
Erasca, Inc.
 2024-04-29 PHASE3
NCT06962254 RECRUITING
Solid Tumor Cancer
China Medical University Hospital
 2025-05-10 PHASE1
NCT04111458 ACTIVE_NOT_RECRUITING
Solid Tumors, KRAS Mutation; SOS1
Boehringer Ingelheim
 2019-11-04 PHASE1
NCT07477457 RECRUITING
Osteosarcoma; Metastasis
Memorial Sloan Kettering Cancer Center
 2026-03-11 PHASE2
NCT02693535 RECRUITING
Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
American Society of Clinical Oncology
 2016-03-14 PHASE2
NCT07010393 NOT_YET_RECRUITING
Thyroid Neoplasms
Fujian Medical University
 2025-07-01 PHASE4
NCT03225664 ACTIVE_NOT_RECRUITING
Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma
M.D. Anderson Cancer Center
 2018-02-03 PHASE1; PHASE2
NCT04485559 RECRUITING
Recurrent World Health Organization (WHO) Grade II Glioma; Low-grade Glioma; High-Grade Glioma (HGG)
University of California, San Francisco
 2020-12-09 PHASE1
NCT01989585 ACTIVE_NOT_RECRUITING
Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Malignant Solid Neoplasm; Metastatic Melanoma; Unresectable Melanoma
National Cancer Institute (NCI)
 2014-03-24 PHASE1; PHASE2
NCT05275374 NOT_YET_RECRUITING
Cancer; BRAF V600 Mutation; Melanoma; Colorectal Cancer; Thyroid Cancer; Nonsmall Cell Lung Cancer
Xynomic Pharmaceuticals, Inc.
 2025-12-31 PHASE1; PHASE2
NCT02910700 ACTIVE_NOT_RECRUITING
Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
M.D. Anderson Cancer Center
 2016-12-09 PHASE2
NCT05874414 RECRUITING
Cholangiocarcinoma
Genfit
 2023-08-21 PHASE1; PHASE2
NCT06967155 ACTIVE_NOT_RECRUITING
Neoplasms
Blokhin's Russian Cancer Research Center
 2025-03-01 PHASE2
NCT06563999 RECRUITING
Lung Cancer Stage III; Mutation
Sun Yat-sen University
 2024-11-01 PHASE2
NCT03975231 RECRUITING
BRAF NP_004324.2:p.V600E; BRAF V600K Mutation Present; Thyroid Gland Anaplastic Carcinoma
City of Hope Medical Center
 2020-09-14 PHASE1
NCT03919071 ACTIVE_NOT_RECRUITING
Anaplastic Astrocytoma; Anaplastic Astrocytoma, Not Otherwise Specified; Anaplastic Ganglioglioma; Anaplastic Pleomorphic Xanthoastrocytoma; Glioblastoma; Malignant Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma
National Cancer Institute (NCI)
 2020-02-20 PHASE2
NCT05525273 RECRUITING
Craniopharyngioma
Eva Marie Erfurth, MD, PhD
 2023-09-01 PHASE2
NCT02925234 RECRUITING
Cancer; Tumors; Neoplasm; Neoplasia
The Netherlands Cancer Institute
 2016-08 PHASE2
NCT06804824 RECRUITING
Advanced Solid Tumors
Vividion Therapeutics, Inc.
 2025-02-25 PHASE1
NCT07072403 ACTIVE_NOT_RECRUITING
Vascular Anomalies
West China Hospital
 2025-07-07 PHASE1; PHASE2
NCT04943224 RECRUITING
Histiocytosis
Anna Raciborska
 2021-04-01 PHASE2
NCT04238624 ACTIVE_NOT_RECRUITING
Anaplastic Thyroid Cancer; Thyroid Cancer; BRAF Gene Mutation; BRAF Mutation-Related Tumors
Memorial Sloan Kettering Cancer Center
 2020-01-20 PHASE2
NCT02231775 ACTIVE_NOT_RECRUITING
Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7
M.D. Anderson Cancer Center
 2014-10-22 PHASE2
NCT02196181 ACTIVE_NOT_RECRUITING
Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
National Cancer Institute (NCI)
 2014-09-19 PHASE2
NCT03363217 ACTIVE_NOT_RECRUITING
Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System Glioma
St. Justine's Hospital
 2018-08-16 PHASE2
NCT04417621 ACTIVE_NOT_RECRUITING
Melanoma
Novartis Pharmaceuticals
 2020-10-30 PHASE2
NCT03087071 ACTIVE_NOT_RECRUITING
EGFR NP_005219.2:p.S492R; KRAS Gene Mutation; MAP2K1 Gene Mutation; Metastatic Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
M.D. Anderson Cancer Center
 2017-12-29 PHASE2
NCT06079333 RECRUITING
Anaplastic Thyroid Cancer
Leiden University Medical Center
 2023-01-01 PHASE2
NCT06653517 RECRUITING
Ameloblastoma; BRAF V600E Mutation Positive
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
 2023-01-01 PHASE2
NCT02465060 ACTIVE_NOT_RECRUITING
Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma
National Cancer Institute (NCI)
 2015-08-17 PHASE2
NCT06739395 RECRUITING
Solid Tumor; Precision Medicine
Tianjin Medical University Second Hospital
 2024-11-01 PHASE2
NCT06195228 RECRUITING
Advanced Thyroid Cancer Patients Who Received Target Therapy
Fudan University
 2020-01-01 PHASE4
NCT04185883 ACTIVE_NOT_RECRUITING
Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Amgen
 2019-12-17 PHASE1
NCT05159245 RECRUITING
Advanced Cancer; Solid Tumor; Haematological Malignancy
Helsinki University Central Hospital
 2021-12-10 PHASE2
NCT03975829 ACTIVE_NOT_RECRUITING
Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneuronal Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Liponeurocytoma; Neurofibromatosis Type 1
Novartis Pharmaceuticals
 2019-11-04 PHASE4
NCT04675710 ACTIVE_NOT_RECRUITING
Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Squamous Cell Carcinoma
M.D. Anderson Cancer Center
 2021-06-24 PHASE2
NCT05372354 RECRUITING
Multiple Myeloma
Bristol-Myers Squibb
 2022-10-18 PHASE1; PHASE2
NCT03333343 ACTIVE_NOT_RECRUITING
EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals
 2018-01-29 PHASE1
NCT04116541 RECRUITING
Malignant Solid Tumor
Centre Leon Berard
 2020-01-28 PHASE2
NCT05358249 ACTIVE_NOT_RECRUITING
KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Neoplasms, Colorectal
Novartis Pharmaceuticals
 2022-10-24 PHASE1; PHASE2
NCT04544111 ACTIVE_NOT_RECRUITING
Thyroid Cancer; Thyroid Cancer, Follicular; Papillary Thyroid Cancer; Follicular Thyroid Cancer; Hurthle Cell Tumor; Poorly Differentiated Thyroid Gland Carcinoma; Hurthle Cell Thyroid Neoplasia
Memorial Sloan Kettering Cancer Center
 2020-09-02 PHASE2
NCT03085056 ACTIVE_NOT_RECRUITING
Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
 2017-03-15 EARLY_PHASE1
NCT06555237 RECRUITING
Cardiomegaly; Noonan Syndrome
Medical University of Warsaw
 2024-08-01 PHASE2
NCT03091257 ACTIVE_NOT_RECRUITING
Multiple Myeloma
Massachusetts General Hospital
 2017-06-21 PHASE1
NCT06456138 NOT_YET_RECRUITING
KRAS Mutation-Related Tumors; Advanced Lung Cancer; Refractory Tumor
Shanghai Chest Hospital
 2024-07-01 PHASE1; PHASE2
NCT03065387 TERMINATED
Advanced Malignant Solid Neoplasm; EGFR Gene Amplification; EGFR Gene Mutation; ERBB2 Gene Amplification; ERBB2 Gene Mutation; ERBB3 Gene Mutation; ERBB4 Gene Mutation; KRAS Gene Mutation; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm
M.D. Anderson Cancer Center
 2017-10-31 PHASE1
NCT04201457 ACTIVE_NOT_RECRUITING
Low Grade Glioma (LGG) of Brain With BRAF Aberration; High Grade Glioma (HGG) of the Brain With BRAF Aberration; Low Grade Glioma of Brain With Neurofibromatosis Type 1
Pediatric Brain Tumor Consortium
 2020-01-17 PHASE1; PHASE2
NCT04892017 TERMINATED
Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor
Deciphera Pharmaceuticals, LLC
 2021-06-15 PHASE1
NCT06098872 WITHDRAWN
Arteriovenous Malformations
University Health Network, Toronto
 2024-01-30 PHASE2
NCT06362694 UNKNOWN
Anaplastic Thyroid Cancer
Saint Petersburg State University, Russia
 2024-03-25 PHASE2
NCT05518110 TERMINATED
Pancreatic Cancer
Cancer Trials Ireland
 2023-05-31 PHASE2
NCT05876806 UNKNOWN
Cancer
Se Jun Park
 2023-06-20 PHASE2
NCT04258046 COMPLETED
Venous Malformation; Arterial Disease
Stanford University
 2020-12-01 PHASE2
NCT03631953 UNKNOWN
Meningioma
Assistance Publique Hopitaux De Marseille
 2019-09-30 PHASE1
NCT05668585 COMPLETED
Solid Tumors; Melanoma; NSCLC; CRC; ATC
C4 Therapeutics, Inc.
 2022-12-08 PHASE1
NCT02645149 COMPLETED
Melanoma
Melanoma Institute Australia
 2021-11-22 PHASE2
NCT04557956 ACTIVE_NOT_RECRUITING
Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma
National Cancer Institute (NCI)
 2021-08-19 PHASE1; PHASE2
NCT06902792 ENROLLING_BY_INVITATION
Histiocytosis, Langerhans-Cell
Second Affiliated Hospital of Wenzhou Medical University
 2025-02-06 PHASE1
NCT05677373 WITHDRAWN
Advanced Uveal Melanoma; Metastatic Uveal Melanoma; Unresectable Uveal Melanoma
Alliance for Clinical Trials in Oncology
 2023-01-13 PHASE1; PHASE2
NCT05907304 ACTIVE_NOT_RECRUITING
Advanced or Metastatic Solid Tumors
Erasca, Inc.
 2023-08-17 PHASE1
NCT05440942 COMPLETED
Pancreatic Ductal Adenocarcinoma
Peter Hosein, MD
 2023-01-19 PHASE1
NCT06054191 NOT_YET_RECRUITING
NSCLC; BRAF V600 Mutation; MET Exon 14 Mutation
Sun Yat-sen University
 2024-02-01 PHASE2
NCT04940052 ACTIVE_NOT_RECRUITING
Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals
 2021-11-15 PHASE3
NCT03026517 COMPLETED
Melanoma
Memorial Sloan Kettering Cancer Center
 2017-01 PHASE1
NCT03825289 TERMINATED
Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unresectable Pancreatic Carcinoma
University of Utah
 2019-01-30 PHASE1
NCT04619316 UNKNOWN
Metastatic Thyroid Cancer
University Hospital, Essen
 2018-02-05 PHASE2
NCT05182931 UNKNOWN
Thyroid Cancer
Olivia Newton-John Cancer Research Institute
 2022-07-14 PHASE2
NCT02070549 COMPLETED
Advanced Malignant Solid Neoplasm; Metastatic Malignant Neoplasm in the Liver; Metastatic Malignant Solid Neoplasm; Unresectable Solid Neoplasm
National Cancer Institute (NCI)
 2014-03-10 PHASE1
NCT06482086 RECRUITING
Locally Advanced Thyroid Gland Carcinoma
West China Hospital
 2021-06-01 PHASE2
NCT05275374 Not yet recruiting
Cancer|BRAF V600 Mutation|Melanoma|Colorectal Cancer|Thyroid Cancer|Nonsmall Cell Lung Cancer
Xynomic Pharmaceuticals Inc.
 2024-12 Phase 1|Phase 2
NCT04454476 UNKNOWN
Gastric Cancer; Metaplasia; Stage I Gastric Cancer; Initial-onset Gastric Cancer
Vanderbilt-Ingram Cancer Center
 2022-11-09 PHASE1
NCT04452877 COMPLETED
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals
 2020-08-19 PHASE2
NCT03377361 COMPLETED
Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm
Bristol-Myers Squibb
 2018-01-31 PHASE1; PHASE2
NCT04294160 TERMINATED
BRAF V600 Colorectal Cancer
Novartis Pharmaceuticals
 2020-07-22 PHASE1
NCT01990196 ACTIVE_NOT_RECRUITING
Prostate Cancer
Jonsson Comprehensive Cancer Center
 2014-09-23 PHASE2
NCT03741101 UNKNOWN
Neurofibromatosis 1; Child; Neurofibroma, Plexiform
Region Skane
 2019-06-10 PHASE2
NCT04965220 UNKNOWN
Solid Tumor
Shanghai Henlius Biotech
 2022-01-05 PHASE1
NCT03563729 RECRUITING
Malignant Melanoma
Inge Marie Svane
 2018-06-06 PHASE2
NCT02872259 COMPLETED
Melanoma
Haukeland University Hospital
 2017-02-13 PHASE1; PHASE2
NCT02974725 TERMINATED
Non-Small Cell Lung Cancer; Melanoma
Novartis Pharmaceuticals
 2017-02-24 PHASE1
NCT02881242 ACTIVE_NOT_RECRUITING
Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer
Jonsson Comprehensive Cancer Center
 2018-01-30 PHASE2
NCT04527549 TERMINATED
Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma
ECOG-ACRIN Cancer Research Group
 2021-06-01 PHASE2
NCT04739566 WITHDRAWN
Thyroid Gland Anaplastic Carcinoma
Saint Petersburg State University, Russia
 2021-01-22 PHASE2
NCT03784014 COMPLETED
Soft Tissue Sarcoma
Institut National de la Santé Et de la Recherche Médicale, France
 2019-10-19 PHASE3
NCT05435846 TERMINATED
Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer
Collin Blakely
 2022-08-10 PHASE1
NCT04439292 ACTIVE_NOT_RECRUITING
Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
National Cancer Institute (NCI)
 2016-01-04 PHASE2
NCT06098872 Not yet recruiting
Arteriovenous Malformations
University Health Network Toronto
 2023-11 Phase 2
NCT04310397 TERMINATED
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8
M.D. Anderson Cancer Center
 2020-01-29 PHASE2
NCT02224781 ACTIVE_NOT_RECRUITING
Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma
National Cancer Institute (NCI)
 2015-09-08 PHASE3
NCT03714958 COMPLETED
Colorectal Cancer; Advanced Cancer; Metastatic Cancer
Centre Leon Berard
 2018-12-20 PHASE1
NCT03455764 COMPLETED
Melanoma
Dana-Farber Cancer Institute
 2018-09-10 PHASE1; PHASE2
NCT05907304 Recruiting
Advanced or Metastatic Solid Tumors
Erasca Inc.
 2023-08-17 Phase 1
NCT05874414 Recruiting
Cholangiocarcinoma
Genfit
 2023-08-21 Phase 1|Phase 2
NCT03317119 COMPLETED
Metastatic Colon Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Carcinoma; RAS Family Gene Mutation; Stage III Colon Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7
City of Hope Medical Center
 2018-04-11 PHASE1
NCT04967079 COMPLETED
Non Small Cell Lung Cancer
Shanghai Chest Hospital
 2021-08-01 PHASE1
NCT04059224 COMPLETED
Stage IV Melanoma; Stage III Melanoma
Universitair Ziekenhuis Brussel
 2019-01-28 PHASE2
NCT04303403 UNKNOWN
Colorectal Cancer; Pancreatic Adenocarcinoma
National Cancer Centre, Singapore
 2018-07-31 PHASE1
NCT03148275 COMPLETED
Locally Advanced Epithelioid Hemangioendothelioma; Metastatic Epithelioid Hemangioendothelioma; Unresectable Epithelioid Hemangioendothelioma
National Cancer Institute (NCI)
 2017-06-20 PHASE2
NCT04326283 TERMINATED
Amyotrophic Lateral Sclerosis
Genuv Inc.
 2020-04-02 PHASE1; PHASE2
NCT03190915 ACTIVE_NOT_RECRUITING
Juvenile Myelomonocytic Leukemia; Neurofibromatosis Type 1
National Cancer Institute (NCI)
 2018-09-09 PHASE2
NCT05299580 WITHDRAWN
Melanoma
Fondazione Melanoma Onlus
 2021-02-18 PHASE2
NCT05071183 TERMINATED
KRAS Mutation-Related Tumors; Metastatic Solid Tumor; Advanced Solid Tumor
Turning Point Therapeutics, Inc.
 2021-09-23 PHASE1; PHASE2
NCT05048134 TERMINATED
Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
 2021-10-25 PHASE1
NCT04487106 COMPLETED
Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome
M.D. Anderson Cancer Center
 2020-07-21 PHASE2
NCT03979651 COMPLETED
Metastatic NRAS Melanoma
Hospices Civils de Lyon
 2019-10-15
NCT05616923 COMPLETED
Rosacea, Erythematotelangiectatic
Albany Research Institute, Inc.
 2021-11-01 PHASE1
NCT04801966 TERMINATED
Cancer
Peter MacCallum Cancer Centre, Australia
 2021-09-23
NCT02079740 ACTIVE_NOT_RECRUITING
Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm
National Cancer Institute (NCI)
 2014-03-26 PHASE1; PHASE2
NCT03501368 COMPLETED
Melanoma; Unresectable Melanoma; Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
 2018-06-27 PHASE1
NCT03434262 COMPLETED
Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Ganglioglioma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Pleomorphic Xanthoastrocytoma, Anaplastic; Atypical Teratoid/Rhabdoid Tumor; Brain Cancer; Brain Tumor; Central Nervous System Neoplasms; Choroid Plexus Carcinoma; CNS Embryonal Tumor With Rhabdoid Features; Ganglioneuroblastoma of Central Nervous System; CNS Tumor; Embryonal Tumor of CNS; Ependymoma; Glioblastoma; Glioma; Glioma, Malignant; Medulloblastoma; Medulloblastoma; Unspecified Site; Medulloepithelioma; Neuroepithelial Tumor; Neoplasms; Neoplasms, Neuroepithelial; Papillary Tumor of the Pineal Region (High-grade Only); Pediatric Brain Tumor; Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only); Pineoblastoma; Primitive Neuroectodermal Tumor; Recurrent Medulloblastoma; Refractory Brain Tumor; Neuroblastoma. CNS; Glioblastoma, IDH-mutant; Glioblastoma, IDH-wildtype; Medulloblastoma, Group 3; Medulloblastoma, Group 4; Glioma, High Grade; Neuroepithelial Tumor, High Grade; Medulloblastoma, SHH-activated and TP53 Mutant; Medulloblastoma, SHH-activated and TP53 Wildtype; Medulloblastoma, Chromosome 9q Loss; Medulloblastoma, Non-WNT Non-SHH, NOS; Medulloblastoma, Non-WNT/Non-SHH; Medulloblastoma, PTCH1 Mutation; Medulloblastoma, WNT-activated; Ependymoma, Recurrent; Glioma, Recurrent High Grade; Glioma, Recurrent Malignant; Embryonal Tumor, NOS; Glioma, Diffuse Midline, H3K27M-mutant; Embryonal Tumor With Multilayered Rosettes (ETMR); Ependymoma, NOS, WHO Grade III; Ependymoma, NOS, WHO Grade II; Medulloblastoma, G3/G4; Ependymoma, RELA Fusion Positive
St. Jude Children's Research Hospital
 2018-03-05 PHASE1
NCT03516214 COMPLETED
Bronchial Neoplasms
University of Cologne
 2018-04-25 PHASE1
NCT03668431 UNKNOWN
Metastatic Colorectal Cancer
Massachusetts General Hospital
 2018-10-15 PHASE2
NCT03244956 COMPLETED
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
Gustave Roussy, Cancer Campus, Grand Paris
 2017-12-27 PHASE2
NCT04566133 TERMINATED
Bile Duct Cancer; Biliary Cancer; Biliary Tract Neoplasms; Cholangiocarcinoma
National Cancer Institute (NCI)
 2022-02-15 PHASE2
NCT03428126 COMPLETED
Malignant Neoplasms of Digestive Organs; Colorectal Cancer; Colon Cancer
M.D. Anderson Cancer Center
 2018-03-21 PHASE2
NCT03087448 TERMINATED
Non-small Cell Lung Cancer
University of California, San Francisco
 2017-09-09 PHASE1
NCT01723202 COMPLETED
Follicular Thyroid Cancer; Insular Thyroid Cancer; Papillary Thyroid Cancer; Recurrent Thyroid Cancer
Bhavana Konda
 2012-11-07 PHASE2
NCT03704688 COMPLETED
Non Small Cell Lung Cancer; KRAS Gene Mutation
Memorial Sloan Kettering Cancer Center
 2018-10-09 PHASE1; PHASE2
NCT02858921 ACTIVE_NOT_RECRUITING
Melanoma
Melanoma Institute Australia
 2017-11-08 PHASE2
NCT03149029 ACTIVE_NOT_RECRUITING
Metastatic Melanoma
Massachusetts General Hospital
 2017-11-27 PHASE2
NCT02034110 COMPLETED
Cancer
Novartis Pharmaceuticals
 2014-03-12 PHASE2
NCT03754179 UNKNOWN
Melanoma
Universitair Ziekenhuis Brussel
 2018-01-23 PHASE1; PHASE2
NCT04554680 UNKNOWN
Thyroid Cancer
National University Hospital, Singapore
 2020-12-30 PHASE2
NCT04652258 TERMINATED
Pyrexia
University of Zurich
 2021-02-01 PHASE2
NCT02257424 COMPLETED
Advanced BRAF Mutant Melanoma
Abramson Cancer Center at Penn Medicine
 2014-10 PHASE1; PHASE2
NCT01740648 COMPLETED
Recurrent Rectal Cancer; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer
Ohio State University Comprehensive Cancer Center
 2012-11-26 PHASE1
NCT02152995 ACTIVE_NOT_RECRUITING
Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma; Stage IV Thyroid Gland Follicular Carcinoma AJCC v7; Stage IV Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
National Cancer Institute (NCI)
 2014-08-14 PHASE2
NCT02684058 COMPLETED
Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneurona Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Iponeurocytoma
Novartis Pharmaceuticals
 2017-12-28 PHASE2
NCT02130466 COMPLETED
Melanoma; Solid Tumors
Merck Sharp & Dohme LLC
 2014-05-29 PHASE1; PHASE2
NCT01827384 COMPLETED
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
 2014-01-07 PHASE2
NCT02900664 COMPLETED
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Novartis Pharmaceuticals
 2016-08-23 PHASE1
NCT03794297 WITHDRAWN
Erdheim-Chester Disease
National Cancer Institute (NCI)
 2019-01-04 PHASE2
NCT03299088 COMPLETED
KRAS Gene Mutation; Metastatic Non-Squamous Non-Small Cell Lung Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7
Jonathan Riess
 2018-06-26 PHASE1
NCT02124772 COMPLETED
Cancer
Novartis Pharmaceuticals
 2015-01-15 PHASE1; PHASE2
NCT03076164 COMPLETED
Lung Adenocarcinoma; Lung Cancer; Lung Cancer Metastatic; Lung Cancer Stage IV; Recurrent Lung Adenocarcinoma; Recurrent Lung Cancer
Memorial Sloan Kettering Cancer Center
 2017-03-01 PHASE1; PHASE2
NCT03878524 TERMINATED
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma
OHSU Knight Cancer Institute
 2020-04-01 PHASE1
NCT02704156 COMPLETED
Pancreatic Cancer
Changhai Hospital
 2016-10 PHASE2
NCT03088176 UNKNOWN
Melanoma; BRAF Gene Mutation
West Cancer Center
 2017-06-25 PHASE1
NCT03551626 COMPLETED
Malignant Melanoma
Novartis Pharmaceuticals
 2018-08-29 PHASE3
NCT04439357 ACTIVE_NOT_RECRUITING
Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
National Cancer Institute (NCI)
 2016-02-25 PHASE2
NCT03266159 WITHDRAWN
Solid Tumours
GlaxoSmithKline
 2017-11-27 PHASE2
NCT02967692 TERMINATED
Melanoma
Novartis Pharmaceuticals
 2017-02-17 PHASE3
NCT02974803 TERMINATED
Melanoma; Brain Metastases
Canadian Cancer Trials Group
 2018-02-09 PHASE2
NCT01940809 TERMINATED
BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7
National Cancer Institute (NCI)
 2013-08-28 PHASE1
NCT02015117 ACTIVE_NOT_RECRUITING
Metastatic Malignant Neoplasm in the Brain
National Cancer Institute (NCI)
 2014-04-28 PHASE1
NCT04439318 ACTIVE_NOT_RECRUITING
Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
National Cancer Institute (NCI)
 2016-02-25 PHASE2
NCT03543306 UNKNOWN
Cancer; Lung Cancer Metastatic; BRAF V600E
Asan Medical Center
 2018-06-30 PHASE2
NCT01750918 COMPLETED
Cancer
Novartis Pharmaceuticals
 2012-12-19 PHASE1; PHASE2
NCT03352947 COMPLETED
Melanoma
Cambridge University Hospitals NHS Foundation Trust
 2017-11-03 PHASE2
NCT03972046 WITHDRAWN
Melanoma (Skin); Melanoma Stage IIIb-IVM1a; Metastasis Skin; Tumor Skin; BRAF Gene Mutation
TriHealth Inc.
 2019-06-24 PHASE2
NCT02342600 WITHDRAWN
Gastrointestinal Stromal Tumors
Sarcoma Alliance for Research through Collaboration
 2017-01 PHASE2
NCT02703571 TERMINATED
Solid Tumors for Phase Ib; Pancreatic Cancer for Phase II; Colorectal Cancer for Phase II
Novartis Pharmaceuticals
 2016-06-29 PHASE1
NCT02392871 COMPLETED
Metastatic Melanoma
Melanoma and Skin Cancer Trials Limited
 2015-05 PHASE1; PHASE2
NCT03232892 TERMINATED
Non-small Cell Lung Cancer
University of California, San Francisco
 2018-02-13 PHASE2
NCT02672358 WITHDRAWN
Non-Small-Cell Lung Cancer
Novartis Pharmaceuticals
 2018-09-03 PHASE2
NCT01989598 COMPLETED
Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
National Cancer Institute (NCI)
 2013-10-30 PHASE2
NCT02705963 COMPLETED
Solid Tumors
Novartis Pharmaceuticals
 2016-10-20 PHASE1
NCT02230553 COMPLETED
Colorectal Cancer
The Netherlands Cancer Institute
 2014-10-07 PHASE1; PHASE2
NCT03272464 TERMINATED
Melanoma
Massachusetts General Hospital
 2019-05-29 PHASE1
NCT02642042 ACTIVE_NOT_RECRUITING
KRAS Gene Mutation; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7
National Cancer Institute (NCI)
 2016-07-18 PHASE2
NCT02101788 COMPLETED
Borderline Ovarian Serous Tumor; Micropapillary Serous Carcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Ovarian Low Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)
 2014-04-11 PHASE2; PHASE3
NCT02399943 COMPLETED
Colorectal Cancer; KRAS Wildtype; NRAS Wildtype; BRAF Wildtype
University Health Network, Toronto
 2015-06 PHASE2
NCT02097225 TERMINATED
BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Solid Neoplasm
National Cancer Institute (NCI)
 2014-05-29 PHASE1
NCT04439279 ACTIVE_NOT_RECRUITING
Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
National Cancer Institute (NCI)
 2015-08-12 PHASE2
NCT02110355 COMPLETED
Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors; Melanoma
Kartos Therapeutics, Inc.
 2014-12-19 PHASE1
NCT02292173 COMPLETED
Hepatocellular Cancer; Liver Cancer
H. Lee Moffitt Cancer Center and Research Institute
 2015-02-18 PHASE1
NCT02367859 COMPLETED
Ameloblastoma; BRAF Gene Mutation
Stanford University
 2017-07-17 PHASE2
NCT02447939 WITHDRAWN
Melanoma
GlaxoSmithKline
 2017-05 PHASE1
NCT03580382 TERMINATED
Melanoma
NYU Langone Health
 2018-07-06 PHASE1; PHASE2
NCT02281760 COMPLETED
BRAF V600E Mutation
National Human Genome Research Institute (NHGRI)
 2014-11-01 PHASE2
NCT03391050 TERMINATED
Melanoma
Aprea Therapeutics
 2018-01-18 PHASE1; PHASE2
NCT02939846 WITHDRAWN
Cancer
GlaxoSmithKline
 2017-05 PHASE1
NCT02296112 COMPLETED
Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Vanderbilt-Ingram Cancer Center
 2015-01 PHASE2
NCT02410863 TERMINATED
Malignant Melanoma
Prof. Dr. med. Dirk Schadendorf
 2015-11 PHASE2
NCT02625337 UNKNOWN
Metastatic Melanoma
The Netherlands Cancer Institute
 2016-01 PHASE2
NCT01902173 COMPLETED
Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma
National Cancer Institute (NCI)
 2013-10-08 PHASE1; PHASE2
NCT02027961 COMPLETED
Melanoma
MedImmune LLC
 2013-12-20 PHASE1
NCT01231594 COMPLETED
Cancer
Novartis Pharmaceuticals
 2010-11-05 PHASE1
NCT02083354 COMPLETED
Cancer; Melanoma
Novartis Pharmaceuticals
 2014-03-18 PHASE2
NCT01376310 TERMINATED
Cancer
Novartis Pharmaceuticals
 2010-11-02 PHASE2
NCT02296996 COMPLETED
Malignant Melanoma
Universitair Ziekenhuis Brussel
 2014-10 PHASE2
NCT02143050 WITHDRAWN
Melanoma
University of Louisville
 2014-09 PHASE1; PHASE2
NCT01912625 TERMINATED
Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7
National Cancer Institute (NCI)
 2013-10-28 PHASE1
NCT01726738 COMPLETED
Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma; BRAF Mutant Melanoma
UNC Lineberger Comprehensive Cancer Center
 2013-04-04 PHASE2
NCT01958112 TERMINATED
Cervical Cancer
Dana-Farber Cancer Institute
 2013-10 PHASE2
NCT01979523 ACTIVE_NOT_RECRUITING
Recurrent Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7
National Cancer Institute (NCI)
 2013-11-21 PHASE2
NCT02915666 WITHDRAWN
Melanoma
University of Texas Southwestern Medical Center
 2016-10 PHASE1
NCT01682083 COMPLETED
Melanoma
Novartis Pharmaceuticals
 2013-01-08 PHASE3
NCT02428270 COMPLETED
Pancreatic Cancer; Adenocarcinoma
University Health Network, Toronto
 2016-04 PHASE2
NCT02039947 COMPLETED
Melanoma and Brain Metastases
Novartis Pharmaceuticals
 2014-02-21 PHASE2
NCT01972347 COMPLETED
Melanoma
Melanoma Institute Australia
 2014-10-01 PHASE2
NCT02292732 WITHDRAWN
Cancer
GlaxoSmithKline
 2016-02 PHASE1
NCT01978236 TERMINATED
Melanoma and Brain Metastases
GlaxoSmithKline
 2014-04-08 PHASE2
NCT02016729 COMPLETED
Advanced Malignancy; Cancer; Oncology; Oncology Patients; Acute Myeloid Leukemia
Kartos Therapeutics, Inc.
 2014-04-01 PHASE1
NCT02138292 COMPLETED
Melanoma
University of Texas Southwestern Medical Center
 2014-07 PHASE1
NCT01964924 COMPLETED
Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)
 2013-10-02 PHASE2
NCT02314143 TERMINATED
Melanoma
GlaxoSmithKline
 2013-11-13 PHASE2
NCT02042443 COMPLETED
Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IV Childhood Hepatocellular Carcinoma; Stage IV Distal Bile Duct Cancer; Stage IVA Gallbladder Cancer; Stage IVB Gallbladder Cancer; Unresectable Extrahepatic Bile Duct Carcinoma
National Cancer Institute (NCI)
 2014-02 PHASE2
NCT02538627 TERMINATED
Colorectal Cancer; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck
Merrimack Pharmaceuticals
 2015-08 PHASE1
NCT02258607 TERMINATED
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
Sierra Oncology LLC - a GSK company
 2015-03-11 PHASE1
NCT01938443 COMPLETED
Cancer; Neoplasms
GlaxoSmithKline
 2013-11-18 PHASE1
NCT02065063 COMPLETED
Cancer
GlaxoSmithKline
 2014-04-22 PHASE1
NCT02580708 TERMINATED
Non-small Cell Lung Cancer
Clovis Oncology, Inc.
 2015-09-30 PHASE1; PHASE2
NCT01438554 COMPLETED
Solid Tumors; Thyroid Cancer; Soft-tissue Sarcoma; Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 2011-10 PHASE1
NCT02140840 WITHDRAWN
Multiple Myeloma
University of Arkansas
 2015-03 PHASE2
NCT01467310 COMPLETED
Breast Cancer
UNC Lineberger Comprehensive Cancer Center
 2012-01 EARLY_PHASE1
NCT02300935 WITHDRAWN
Melanoma
SCRI Development Innovations, LLC
 2015-12 PHASE1
NCT01907815 TERMINATED
Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
National Cancer Institute (NCI)
 2013-10 PHASE2
NCT01721603 TERMINATED
BRAFV600E Melanoma Patients
University of California, San Francisco
 2013-04 PHASE2
NCT01336634 COMPLETED
Cancer
Novartis Pharmaceuticals
 2011-08-05 PHASE2
NCT01935973 COMPLETED
Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Cancer
National Cancer Institute (NCI)
 2013-09-30 PHASE1
NCT01767454 COMPLETED
Solid Tumours
GlaxoSmithKline
 2013-02-12 PHASE1
NCT01619774 COMPLETED
Melanoma
M.D. Anderson Cancer Center
 2012-09 PHASE2
NCT02357732 WITHDRAWN
Metastatic Melanoma
University of Pittsburgh
 2015-08 PHASE1
NCT01553851 COMPLETED
Neoplasms, Oral; Mouth Neoplasms
Washington University School of Medicine
 2013-02 PHASE2
NCT01701037 TERMINATED
Recurrent Melanoma; Stage IIB Melanoma (Locally Advanced); Stage IIC Melanoma (Locally Advanced); Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma (Limited, Resectable)
Vanderbilt-Ingram Cancer Center
 2013-01 PHASE2
NCT01725100 COMPLETED
Cancer
GlaxoSmithKline
 2013-02-05 PHASE1
NCT01287546 COMPLETED
Advanced Cancer
Eli Lilly and Company
 2010-04-13 PHASE1
NCT01138085 COMPLETED
Cancer
GlaxoSmithKline
 2010-05-04 PHASE1
NCT01155453 COMPLETED
Advanced and Selected Solid Tumors
Novartis Pharmaceuticals
 2010-04 PHASE1
NCT01941927 COMPLETED
Melanoma
Adil Daud
 2013-09-10 PHASE2
NCT01928940 COMPLETED
Solid Tumours
GlaxoSmithKline
 2013-08-15 PHASE2
NCT01943864 COMPLETED
Cancer
GlaxoSmithKline
 2013-09-19 PHASE2
NCT01938456 WITHDRAWN
Lung Cancer, Non-Small Cell
GlaxoSmithKline
 2013-10 PHASE1
NCT01597908 COMPLETED
Melanoma
Novartis Pharmaceuticals
 2012-06-04 PHASE3
NCT01658553 COMPLETED
Cancer
GlaxoSmithKline
 2012-09-19 PHASE1
NCT01248858 TERMINATED
Cancer
GlaxoSmithKline
 2010-12-03 PHASE1
NCT01192165 COMPLETED
Cancer
GlaxoSmithKline
 2010-09-14 PHASE1
NCT01584648 COMPLETED
Melanoma
Novartis Pharmaceuticals
 2012-05-04 PHASE3
NCT01324258 COMPLETED
Solid Tumours
GlaxoSmithKline
 2011-01-24 PHASE1
NCT00920140 COMPLETED
Cancer
GlaxoSmithKline
 2011-05 PHASE2
NCT01476137 COMPLETED
Cancer
GlaxoSmithKline
 2011-10-26 PHASE1
NCT01647659 COMPLETED
Cancer
GlaxoSmithKline
 2012-07-30 PHASE1
NCT01362296 COMPLETED
Lung Cancer, Non-Small Cell
GlaxoSmithKline
 2011-09 PHASE2
NCT01072175 COMPLETED
Cancer
Novartis Pharmaceuticals
 2010-03-26 PHASE2
NCT01231581 COMPLETED
Cancer
GlaxoSmithKline
 2010-08 PHASE2
NCT01416337 COMPLETED
Cancer
GlaxoSmithKline
 2011-06-20 PHASE1
NCT00955773 COMPLETED
Cancer
GlaxoSmithKline
 2009-08-17 PHASE1
NCT01245062 COMPLETED
Melanoma
GlaxoSmithKline
 2010-11-22 PHASE3
NCT01371487 COMPLETED
Cancer
GlaxoSmithKline
 2011-05-02 PHASE1
NCT01328106 WITHDRAWN
GNA11 Mutation-positive Metastatic Melanoma; GNAQ Mutation-positive Metastatic Melanoma; Cancer; Metastatic Uveal Melanoma
GlaxoSmithKline
 2010-11 PHASE2
NCT01387204 COMPLETED
Cancer
GlaxoSmithKline
 2011-02-15 PHASE1
NCT01428427 COMPLETED
Leukaemia, Myelocytic, Acute
GlaxoSmithKline
 2009-08-12 PHASE1
NCT01037127 COMPLETED
Cancer
GlaxoSmithKline
 2009-11 PHASE2
NCT00687622 COMPLETED
Solid Tumours
GlaxoSmithKline
 2008-07-28 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-04-07)

Check the Trametinib (GSK1120212) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Trametinib acts as a highly selective, reversible, allosteric inhibitor of MEK1 and MEK2, binding to these dual-specificity kinases to suppress the downstream phosphorylation of ERK and block the mitogen-activated protein kinase pathway. This molecular inhibition induces cell cycle arrest, upregulates p15INK4b and p27KIP1, and triggers apoptosis, thereby suppressing tumor proliferation in clinical conditions such as BRAF V600-mutated melanoma and advanced solid tumors.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.